Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 126

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 126
---
 of that class or the sanction of a special resolution passed at a separate
general meeting of the shares of that class.

Annual and Extraordinary Meetings

Our directors must convene
an annual meeting of shareholders at least once every calendar year. Notice of at least 28 days prior to the date of the meeting is required.
A general meeting may be convened by a directors’ resolution or as otherwise provided in the Corporations Act.

Limitations on the Rights to Own Securities in Our Company

Subject to certain limitations
on the percentage of shares a person may hold in our company, neither our Constitution nor the laws of the Commonwealth of Australia restrict
in any way the ownership or voting of shares in our company.

Changes in Our Capital

Pursuant to the Listing Rules,
our directors may in their discretion issue securities to persons who are not related parties of our company, without the approval of
shareholders, if such issue, when aggregated with securities issued by our company during the previous 12-month period would be an amount
that would not exceed 15% of our issued capital at the commencement of the 12-month period. Other allotments of securities require approval
by an ordinary resolution of shareholders.

C. Material Contracts

License Agreement with NanoMab

In July 2021, Radiopharm entered
into a license agreement with NanoMab Technology Limited (“ NanoMab”). Under the terms of the agreement, NanoMab granted Radiopharm
the exclusive worldwide, sub-licensable right to patents regarding Anti-HER2 Nanobody, anti-TROP2 Nanobody and anti-PTK-7 Nanobody and
a non-exclusive license to certain related know-how connected to the patents licensed.

Subject to the filing of
the Anti-TROP-2 patent, Radiopharm paid an upfront payment of US$12.5 million partly in cash and shares to NanoMab for the license
of the Anti-HER-2, Anti-TROP-2 and Anti-PTK7 antibodies, an upfront payment up to US$12.5 million. Additionally, Radiopharm is
required to pay NanoMab up to US$11.5 million upon the achievement of the several therapeutic milestones and single-digit royalty
rates of Radiopharm’s net sales of each patented licensed product subject to a valid claim.

The agreement is effective,
on a country-by-country and product-by-product developed under the agreement basis, until the later of the fifth anniversary of the expiration
of the last licensed patents or